ResearchIn-Press PreviewEndocrinology
Open Access | 10.1172/jci.insight.151390
1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Find articles by Okuno, Y. in: JCI | PubMed | Google Scholar
1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Find articles by
Fukuhara, A.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Find articles by
Otsuki, M.
in:
JCI
|
PubMed
|
Google Scholar
|
1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Find articles by Shimomura, I. in: JCI | PubMed | Google Scholar
Published July 21, 2022 - More info
Inactivating mutations of ARMC5 are responsible for the development of bilateral macronodular adrenal hyperplasia (BMAH). Although ARMC5 inhibits adrenocortical tumor growth and is considered as tumor-suppressor gene, its molecular function is poorly understood. In this study, through biochemical purification using SREBF (SREBP) as bait, we identified the interaction between SREBF and ARMC5 through its Armadillo repeat. We also found that ARMC5 interacted with CUL3 through its BTB domain and underwent self-ubiquitination. ARMC5 colocalized with SREBF1 in the cytosol and induced proteasome-dependent degradation of full-length SREBF through ubiquitination. Introduction of missense mutations in Armadillo repeat of ARMC5 attenuated the interaction between SREBF, and introduction of mutations found in BMAH completely abolished its ability to degrade full-length SREBF. In H295R adrenocortical cells, silencing of ARMC5 increased full-length SREBFs and upregulated SREBF2 target genes. siARMC5-mediated cell growth was abrogated by simultaneous knockdown of SREBF2 in H295R cells. Our results demonstrated that ARMC5 was a substrate adaptor protein between full-length SREBF and CUL3-based E3 ligase, and suggested the involvement of SREBF pathway in the development of BMAH.